false
0001766140
0001766140
2025-08-15
2025-08-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August
15, 2025
Unicycive Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40582 |
|
81-3638692 |
| (State or other jurisdiction |
|
(Commission File Number) |
|
(IRS Employer |
| of incorporation or organization) |
|
|
|
Identification No.) |
4300 El Camino Real, Suite 210
Los Alto, CA 94022
(Address of principal executive offices)
Registrant’s telephone number, including area
code: (650) 351-4495
(Former name or former address, if changed since last
report)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: |
|
Trading Symbol(s) |
|
Name of each exchange on which registered: |
| Common Stock |
|
UNCY |
|
Nasdaq Capital Market |
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
On August 15, 2025, Unicycive Therapeutics, Inc.
(the “Company”) became aware of a lawsuit purporting to be a securities class action which was filed in United States
District Court for the Northern District of California against the Company and certain of its officers. This action alleges
violations of the federal securities laws in connection with public statements by the Company relating to its new drug application
for oxylanthanum carbonate phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.
The Company believes the claims are meritless and intends to vigorously defend the lawsuit.
SIGNATURE
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 18, 2025
| |
UNICYCIVE THERAPEUTICS, INC. |
| |
|
| |
By: |
/s/ Shalabh Gupta |
| |
|
Shalabh Gupta |
| |
|
Chief Executive Officer |
